• Issue

    Journal of Viral Hepatitis: Volume 25, Issue 5

    i, 439-615
    May 2018
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

COVER IMAGE

Free Access

Cover Image

S. A. Read,  G. Parnell,  D. Booth,  M. W. Douglas,  J. George,  G. Ahlenstiel, 
  • Page: i
  • First Published: 24 April 2018
Cover Image

The cover image, by S. A. Read et al., is based on the Original Article The antiviral role of zinc and metallothioneins in hepatitis C infection, DOI: 10.1111/jvh.12845.

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 439-441
  • First Published: 24 April 2018

NON-COMMISSIONED REVIEW

Open Access

Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review

A. J. Walker,  C. J. Peacock,  V. Pedergnana,  STOP-HCV Consortium ,  W. L. Irving, 
  • Pages: 442-456
  • First Published: 03 February 2018

ORIGINAL ARTICLES

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study

A. Brown,  C. Hézode,  E. Zuckerman,  G. R. Foster,  A. Zekry,  S. K. Roberts,  F. Lahser,  C. Durkan,  C. Badshah,  B. Zhang,  M. Robertson,  J. Wahl,  E. Barr,  B. Haber, on behalf of the C-SCAPE Study Investigators , 
  • Pages: 457-464
  • First Published: 20 November 2017

IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR

C. Carlton-Smith,  J. A. Holmes,  S. Naggie,  A. Lidofsky,  G. M. Lauer,  A. Y. Kim,  R. T. Chung,  on behalf of the ACTG A5327 study group , 
  • Pages: 465-472
  • First Published: 29 November 2017

Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study

M. Alavi,  N. Z. Janjua,  M. Chong,  J. Grebely,  E. J. Aspinall,  H. Innes,  H. Valerio,  B. Hajarizadeh,  P. C. Hayes,  M. Krajden,  J. Amin,  M. G. Law,  J. George,  D. J. Goldberg,  S. J. Hutchinson,  G. J. Dore, 
  • Pages: 473-481
  • First Published: 30 November 2017

Establishing the cascade of care for hepatitis C in England—benchmarking to monitor impact of direct acting antivirals

R. Simmons,  G. Ireland,  W. Irving,  M. Hickman,  C. Sabin,  S. Ijaz,  M. Ramsay,  S. Lattimore,  S. Mandal, 
  • Pages: 482-490
  • First Published: 14 December 2017

The antiviral role of zinc and metallothioneins in hepatitis C infection

S. A. Read,  G. Parnell,  D. Booth,  M. W. Douglas,  J. George,  G. Ahlenstiel, 
  • Pages: 491-501
  • First Published: 14 December 2017

Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis

A. Erman,  A. Sathya,  A. Nam,  J. M. Bielecki,  J. J. Feld,  H-H. Thein,  W. W. L. Wong,  P. Grootendorst,  M. D. Krahn, 
  • Pages: 502-513
  • First Published: 14 December 2017
Open Access

Assessing uncertainty in the burden of hepatitis C virus: Comparison of estimated disease burden and treatment costs in the UK

F. Gubay,  R. Staunton,  C. Metzig,  I. Abubakar,  P. J. White, 
  • Pages: 514-523
  • First Published: 23 December 2017
Open Access

Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing

A. L. McNaughton,  V. B. Sreenu,  G. Wilkie,  R. Gunson,  K. Templeton,  E. C. M. Leitch, 
  • Pages: 524-534
  • First Published: 23 December 2017

The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort

R. Kozuka,  H. Hai,  H. Motoyama,  A. Hagihara,  H. Fujii,  S. Uchida-Kobayashi,  H. Morikawa,  M. Enomoto,  Y. Murakami,  N. Kawada,  A. Tamori, 
  • Pages: 535-542
  • First Published: 23 December 2017

Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir

Yao-Chun Hsu,  Hsiu-J. Ho,  Teng-Yu Lee,  Yen-Tsung Huang,  Ming-Shiang Wu,  Jaw-Town Lin,  Chun-Ying Wu,  Hashem B. El-Serag, 
  • Pages: 543-551
  • First Published: 28 November 2017

Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B

J. Y. Nam,  Y. Chang,  H. Cho,  S. H. Kang,  Y. Y. Cho,  E. J. Cho,  J.-H. Lee,  S. J. Yu,  J.-H. Yoon,  Y. J. Kim, 
  • Pages: 552-560
  • First Published: 01 December 2017

Knowledge regarding hepatitis B mother-to-child transmission among healthcare workers in South China

Y. Chen,  C. Xie,  Y. Zhang,  Y. Li,  S. Ehrhardt,  C. L. Thio,  K. E. Nelson,  Y. Chen,  C.-S. Lin, 
  • Pages: 561-570
  • First Published: 30 November 2017
Open Access

Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: A population-based cohort study using the UK Clinical Practice Research Datalink

G. L. C. Ferreira,  C. Marano,  L. De Moerlooze,  A. Guignard,  Y. Feng,  Y. El Hahi,  T. van Staa, 
  • Pages: 571-580
  • First Published: 08 December 2017

Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B

D.-P. Liu,  W. Lu,  Z.-Q. Zhang,  Y.-B. Wang,  R.-R. Ding,  X.-L. Zhou,  D. Huang,  X.-F. Li, 
  • Pages: 581-589
  • First Published: 12 December 2017

The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients

C.-H. Chen,  Y.-C. Hsu,  S.-N. Lu,  C.-H. Hung,  J.-H. Wang,  C.-M. Lee,  T.-H. Hu, 
  • Pages: 590-597
  • First Published: 23 December 2017

Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B

Y. Wang,  X. Liang,  J. Yang,  H. Wang,  D. Tan,  S. Chen,  J. Cheng,  Y. Chen,  J. Sun,  F. Rong,  W. Yang,  H. Liu,  Z. Liu,  Y. Zheng,  J. Liang,  S. Li,  Z. Liu,  J. Hou, 
  • Pages: 598-607
  • First Published: 29 November 2017

SHORT COMMUNICATION

Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy

A. Tamori,  S. Abiru,  H. Enomoto,  K. Kioka,  M. Korenaga,  J. Tani,  M. Enomoto,  M. Sugiyama,  T. Masaki,  N. Kawada,  H. Yatsuhashi,  S. Nishiguchi,  M. Mizokami, 
  • Pages: 608-611
  • First Published: 30 November 2017

LETTERS TO THE EDITOR

Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery

Q.-L. Zeng,  G.-H. Xu,  B. Wang,  Z.-Q. Li,  Z.-J. Yu, 
  • Pages: 612-613
  • First Published: 23 December 2017

HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication

E. Rodríguez de Santiago,  K. Velázquez Kennedy,  M. García González,  F. Gea Rodríguez,  L. Téllez Villajos,  E. Tavío Hernández,  A. Albillos, 
  • Pages: 614-615
  • First Published: 14 December 2017